NCT00304785已完成4 期
Latanoprost Versus Fotil
Pharmaceutical Research Network10 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2005年5月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
- 试验地点
- 10
研究概览
简要总结
To compare the intraocular pressure effect and safety of latanoprost 0.005% given every evening versus PTFC given twice daily.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •adults with primary open-angle or pigment dispersion glaucoma, or ocular hypertension
- •untreated intraocular pressure should be between 24-36 mm Hg inclusive
- •visual acuity should be 5/50 or better in both eyes
排除标准
- •presence of exfoliation syndrome or exfoliation glaucoma
- •contraindications to study medications
- •any anticipated change in systemic hypotensive therapy
研究者
研究点 (10)
Loading locations...
相似试验
已完成
4 期
Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)Primary Open Angle GlaucomaOcular HypertensionNCT01162603Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia40
已完成
4 期
Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.GlaucomaOcular HypertensionNCT00143208Pfizer's Upjohn has merged with Mylan to form Viatris Inc.250
已完成
不适用
Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG PatientsPrimary Open Angle GlaucomaNCT04461249Kasr El Aini Hospital60
已完成
2 期
A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAGOpen-Angle GlaucomaOcular HypertensionNCT01037036Mati Therapeutics Inc.15
已完成
不适用
The efficacy and safety of Latanoprost ophthalmic solution 0.005% Nitten in Japanese open-angle glaucoma patientsglaucomaJPRN-UMIN000034108The University of Tokyo Hospital